Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular Methotrexate and Etoposide for Recurrent Posterior Fossa Tumors
NCT02905110Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Oct 2017
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methotrexate and etoposide in medulloblastoma, ependymoma and Atypical teratoid rhabdoid tumor (ATRT), sponsored by UTHealth Houston. Primary endpoint: Number of patients with grade 3 through grade 5 new neurological adverse events at 4 months. Started Oct 2017; status: completed.
02
Drugs
methotrexateetoposide
03
Conditions
medulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT02905110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905110.